MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., an antibody discovery and development company, today announced initial results from its Phase I study of XmAb®2513 in patients with relapsed Hodgkin lymphoma (HL). XmAb®2513, an antibody drug candidate developed from Xencor’s proprietary antibody engineering technology, was well tolerated in patients who had a median of six prior lines of cancer treatment. The maximum tolerated dose has not yet been reached, as patients continue to do well on therapy with XmAb®2513. In addition, there is early evidence of anti-tumor activity with stable disease or better observed as best response in more than half of the patients evaluable for efficacy. These data were presented in a poster session today at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Orlando, Florida.
